A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase
(PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have
exhausted available treatment options. The purpose of this study is to define a safe dose and
schedule to be used in subsequent development of PRT811.